What are Mentor breast implants made of and how safe are they?

Mentor Breast Implants: Composition and Safety Profile

Mentor breast implants are made of a silicone elastomer shell filled with cohesive silicone gel (MemoryGel technology), and while they demonstrate acceptable safety profiles with low complication rates in augmentation, patients must understand the significant risks including breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), particularly with textured surfaces, and the need for lifelong surveillance. 1

Implant Composition

Mentor MemoryGel implants consist of:

• Outer shell: Silicone elastomer (polymer) that can be manufactured as either smooth or textured (Siltex) surface 1
• Inner fill: Fixed volume of cohesive silicone gel with varying viscosity depending on the specific product line 1
• Surface texture options: Smooth implants or Siltex textured implants with microtexture classification (average surface roughness 29.5-36.1 µm per ISO 14607 standards) 2

The MemoryGel Xtra variant maintains the cohesive gel technology while optimizing shell gel-fill ratios to increase fullness and projection 3.

Safety Profile: Key Risks by Indication

Primary Augmentation (Cosmetic)

10-year Kaplan-Meier cumulative complication rates 4:

• Capsular contracture (Baker III/IV): 12.1% 4
• Rupture: 24.2% 4
• Reoperation: 25.5% 4
• Explantation: 11.6% 4
• Infection: 1.6% 4

Notably, a single-surgeon series demonstrated significantly lower rates with standardized technique: capsular contracture 2.6%, overall revision rate 8.0% at 18.5 months average follow-up, with subglandular placement statistically correlated with higher revision rates 5.

Primary Reconstruction (Post-Mastectomy)

10-year cumulative complication rates are substantially higher 4:

• Capsular contracture: 20.5% 4
• Rupture: 32.7% 4
• Reoperation: 49.0% 4
• Explantation: 33.4% 4
• Infection: 6.2% 4

Revision Surgery Cohorts

Revision procedures carry the highest complication burden, with 10-year capsular contracture rates of 24.4% (revision augmentation) and 36.9% (revision reconstruction) 4.

Critical Safety Concerns

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

This is the most serious mortality risk associated with breast implants 1:

• FDA announced the association in 2011; WHO classified BIA-ALCL as a distinct entity in 2016 1
• Most cases are associated with textured implants 1
• For Mentor Siltex textured implants specifically: 0.0012% risk based on extensive surveillance data 2
• Typical presentation: Delayed peri-implant effusion (>1 year post-surgery), usually 8-10 years after implantation 1
• Pathophysiology: Rare T-cell lymphoma arising in the implant capsule (scar tissue), not breast tissue itself, likely related to chronic inflammatory stimulus 1

FDA-Mandated Patient Counseling Requirements

The FDA requires boxed warnings and standardized informed consent addressing 1:

• BIA-ALCL risk
• Systemic symptoms risk
• Implant-specific complications (rupture, capsular contracture, infection, malposition)
• Mandatory surveillance protocol: Initial ultrasound or MRI at 5-6 years post-implantation, then every 2-3 years thereafter 1

Rupture Detection and Surveillance

Clinical Presentation

• Saline implants: Clinically apparent (deflation visible as saline is resorbed) 1
• Silicone implants: Often asymptomatic, especially intracapsular ruptures (contained by fibrous capsule) 1
• Extracapsular rupture: May present with palpable masses or breast contour changes as silicone migrates into breast tissue 1

Imaging Recommendations

MRI without contrast is the gold standard 1:

• Sensitivity: 87-96% 1
• Specificity: 77-90% 1
• Classic signs: "Linguini sign" (complete intracapsular rupture), "keyhole sign" (incomplete rupture) 1

Ultrasound has evolving utility 1:

• Excellent for extracapsular silicone detection (classic "snowstorm" pattern) 1
• Recent data shows improved accuracy: 94.7% diagnostic accuracy, 98.3% sensitivity when ≥2 rupture signs present 1
• If only 1 rupture sign detected on ultrasound, MRI confirmation recommended 1

Mammography has limited utility 1:

• Cannot detect intracapsular rupture 1
• Useful only for identifying extracapsular silicone (high-density material outside implant contour) 1

Textured vs. Smooth Surface Trade-offs

Siltex textured implants demonstrated risk-reduction benefits in the Core Study 2:

• Lower capsular contracture reoperation rate in subglandular primary augmentation: 4.21% vs. 19.84% for smooth implants over 10 years 2
• Lower asymmetry reoperation rate in primary reconstruction: 3.88% vs. 11.1% for smooth implants 2

However, textured implants carry higher BIA-ALCL risk 1, 2, creating a risk-benefit calculation that must be individualized based on patient priorities regarding capsular contracture prevention versus lymphoma risk.

Common Pitfalls and Caveats

• Rupture rates increase with implant age: The 24-32% rupture rates at 10 years underscore that these are not lifetime devices 4
• Reconstruction patients face substantially higher complication rates than augmentation patients across all metrics 4
• Subglandular placement increases revision risk compared to submuscular placement 5
• Clinical examination is unreliable for rupture detection; imaging surveillance is mandatory 1
• PET/CT has important limitations for BIA-ALCL: Cannot distinguish benign from malignant effusions (false negatives), and normal inflammatory activity around capsules can cause false positives 1

Quality of Life Outcomes

BREAST-Q data from the MemoryGel Xtra trial demonstrated significant improvements at 1 year 3:

• Satisfaction with breasts
• Psychosocial well-being
• Sexual well-being

These improvements were consistent across augmentation and reconstruction cohorts 3.